Eribulin Mesylate Injection
Product Images NDC 71731-4171

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eribulin Mesylate (NDC 71731-4171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Draft Carton Label (Draft Carton Label)

Draft Carton Label (Draft Carton Label)
The image shows the packaging label for Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL), an intravenous injection. The label includes warnings that it is a sterile cytotoxic agent and single-dose vial. It is manufactured for The WhiteOak Group, LLC, Washington DC, made in China. Storage temperature instructions and dosage information are also present, along with barcodes and a QR code.*
FDA Label Image

Draft Container Label (Draft Container Label)

Draft Container Label (Draft Container Label)
Label for Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) sterile solution for intravenous use. The single-dose vial is to discard unused portions. Storage instructions indicate controlled room temperature with no freezing or refrigeration. Manufactured for The WhiteOak Group, LLC, Washington DC, made in China. The label includes a caution for cytotoxic agent.*
FDA Label Image

Figure 1 (Fig 1)

Figure 1 (Fig 1)
A Kaplan-Meier survival curve chart comparing the proportion of patients alive over time in months for Eribulin Mesylate (N=508) versus a control group (N=254). The chart shows higher survival proportions for Eribulin Mesylate throughout the 36-month period, with the number of patients at risk indicated below the x-axis at various time points.*
FDA Label Image

Figure 2 (Fig 2)

Figure 2 (Fig 2)
A survival probability Kaplan-Meier curve comparing Eribulin Mesylate and Dacarbazine over survival time in months. The chart shows survival probabilities on the vertical axis and survival time on the horizontal axis, with accompanying numbers of subjects at risk for each treatment group listed below the graph.*
FDA Label Image

Formula Structure (Figure 01 Formula Structure)

Formula Structure (Figure 01 Formula Structure)
Chemical structure of Eribulin Mesylate, showing atomic connectivity and stereochemistry of the molecule along with the mesylate group (CH3-SO3H) indicated separately.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.